Iovance Biotherapeutics, Inc.
No trades
Fundamentals and stats
EPS and revenue snapshot
In the last quarter, the company reported -0.25 USD per share, beating the -0.26 USD estimate by 2.98%. Revenue for the same period reached 67.45 M USD, despite the estimate of 72.85 M USD. For the next quarter, analysts expect -0.17 USD in earnings per share and 81.33 M USD in revenue.
Next report date—
Report period—
EPS estimate—
Revenue estimate—
EPS
Reported
Estimate
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Reported
Estimate
Surprise